Nasopharyngeal carcinoma

MLK Chua, JTS Wee, EP Hui, ATC Chan - The Lancet, 2016‏ - thelancet.com
Epidemiological trends during the past decade suggest that although incidence of
nasopharyngeal carcinoma is gradually declining, even in endemic regions, mortality from …

Head and neck cancers

DG Pfister, KK Ang, DM Brizel, BA Burtness… - Journal of the National …, 2011‏ - jnccn.org
Head and Neck Cancers in: Journal of the National Comprehensive Cancer Network Volume
9 Issue 6 (2011) Jump to Content User Account Sign In to save searches and organize your …

Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as first-line therapy for recurrent or metastatic nasopharyngeal carcinoma: final overall survival analysis of …

S Hong, Y Zhang, G Yu, P Peng, J Peng… - Journal of clinical …, 2021‏ - ascopubs.org
PURPOSE GEM20110714 (ClinicalTrials. gov identifier: NCT01528618), the first
randomized, phase III study of systemic chemotherapy in recurrent or metastatic …

Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal …

L Chen, CS Hu, XZ Chen, GQ Hu, ZB Cheng… - The lancet …, 2012‏ - thelancet.com
Background The effect of the addition of adjuvant chemotherapy to concurrent
chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma is unclear. We …

Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer …

J Wee, EH Tan, BC Tai, HB Wong, SS Leong… - Journal of clinical …, 2005‏ - ascopubs.org
Purpose The Intergroup 00-99 Trial for nasopharyngeal cancer (NPC) showed a benefit of
adding chemotherapy to radiotherapy. However, there were controversies regarding the …

Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma

WK Chia, M Teo, WW Wang, B Lee, SF Ang, WM Tai… - Molecular Therapy, 2014‏ - cell.com
The outcomes for patients with metastatic or locally recurrent Epstein–Barr virus (EBV)-
positive nasopharyngeal carcinoma (NPC) remain poor. Adoptive immunotherapy with EBV …

Concurrent chemo-radiation with or without induction gemcitabine, carboplatin, and paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal …

T Tan, WT Lim, KW Fong, SL Cheah, YL Soong… - International Journal of …, 2015‏ - Elsevier
Purpose To compare survival, tumor control, toxicities, and quality of life of patients with
locally advanced nasopharyngeal carcinoma (NPC) treated with induction chemotherapy …

Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis

N Liu, NY Chen, RX Cui, WF Li, Y Li, RR Wei… - The lancet …, 2012‏ - thelancet.com
Background MicroRNAs (miRNAs) can be used as prognostic biomarkers in many types of
cancer. We aimed to identify miRNAs that were prognostic in patients with nasopharyngeal …

The FOXM1–ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells

Y Hou, Q Zhu, Z Li, Y Peng, X Yu, B Yuan, Y Liu… - Cell death & …, 2017‏ - nature.com
Paclitaxel is clinically used as a first-line chemotherapeutic regimen for several cancer
types, including head and neck cancers. However, acquired drug resistance results in the …

[HTML][HTML] A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic …

WK Chia, WW Wang, M Teo, WM Tai, WT Lim, EH Tan… - Annals of oncology, 2012‏ - Elsevier
ABSTRACT Background Individuals with metastatic Epstein–Barr virus (EBV)-positive
nasopharyngeal carcinoma (NPC) continue to have poor outcomes. To evaluate the ability …